Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. (Nasdaq: CDNA) is a precision medicine company in the medical laboratories industry that focuses on transplant patients and caregivers. The company describes itself as “The Transplant Company” and emphasizes genomics‑based information, non‑invasive molecular testing, and digital health technologies for heart, kidney, and lung transplantation. This news page brings together company announcements and disclosures that illustrate how CareDx develops and commercializes transplant‑focused diagnostics and solutions.
Readers can expect news related to financial results, where CareDx reports revenue across testing services, product revenue, and patient and digital solutions revenue. The company issues press releases on quarterly and preliminary annual performance, highlighting trends in testing services volume and segment‑level revenue. These updates provide context on how its transplant‑focused offerings are used in clinical practice.
CareDx also publishes clinical and scientific updates, including data from the Surveillance HeartCare Outcomes Registry (SHORE) and other transplant studies. These releases describe how HeartCare, AlloSure Heart, and related molecular tests are evaluated as biomarkers for rejection risk, graft dysfunction, and treatment response in heart and kidney transplantation. Product‑focused news, such as the introduction of HistoMap Kidney and other molecular assays, further illustrates the company’s emphasis on transplant diagnostics.
Additional news items cover corporate and governance developments, such as leadership appointments, board changes, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and participation in investor conferences. Together, these updates offer investors, clinicians, and other stakeholders a consolidated view of CareDx’s activities in precision transplant medicine. For ongoing insight into CDNA, this page serves as a central source for company press releases and related disclosures.
CareDx (NASDAQ:CDNA), a precision medicine company specializing in transplant healthcare solutions, has announced its participation in the upcoming Wells Fargo Healthcare Conference. The company will engage in a fireside chat presentation on September 5, 2025, at 8:00 AM ET in Boston, Massachusetts.
Investors and interested parties can access both the live and archived versions of the presentation through the "Events and Presentations" section on CareDx's investor relations website at investors.caredx.com.
CareDx (NASDAQ:CDNA), a precision medicine company focused on transplant healthcare solutions, has appointed Nathan Smith as its new Chief Financial Officer. Smith brings over 14 years of experience in molecular diagnostics, including senior finance roles at Myriad Genetics and CFO positions at Blackrock Neurotech and WIN Brands.
The appointment comes as current CFO Abhishek Jain announces his retirement, though he will continue supporting the company in a consulting capacity to ensure a smooth transition. CEO John Hanna emphasized Smith's operational excellence and experience in scaling diagnostics companies efficiently as key factors for the company's next growth phase.
CareDx (NASDAQ:CDNA) reported Q2 2025 financial results with mixed performance. The company achieved adjusted revenue of $90.5 million, up 14% year-over-year, while testing services volume grew 13% to 49,500 tests. AlloSure Kidney testing volumes showed strong growth of nearly 20% year-over-year.
The company reported a GAAP net loss of $8.6 million ($0.16 per share) but achieved non-GAAP net income of $5.6 million ($0.10 per share). CareDx maintains a strong balance sheet with $186 million in cash after completing a $50 million share repurchase. The company narrowed its full-year 2025 revenue guidance to $367-373 million and maintained adjusted EBITDA guidance of $29-33 million.
Notable business achievements include the publication of the KOAR manuscript, launch of AlloSure Plus AI-driven diagnostic platform, and successful EPIC environment installation.
CareDx (NASDAQ: CDNA) has published its landmark Kidney Allograft Outcomes AlloSure Registry (KOAR) study in the American Journal of Transplantation, demonstrating the clinical utility of its AlloSure® donor-derived cell-free DNA (dd-cfDNA) test in kidney transplant surveillance.
The extensive study, involving 1,743 patients across 56 U.S. transplant centers and 18,584 AlloSure tests, revealed that elevated AlloSure was associated with a 6-fold increase in rejection detection in surveillance biopsies and a 4-fold increase in for-cause biopsies. The test can detect rejection up to four months before antibody-mediated rejection (ABMR) and one month before T-cell mediated rejection (TCMR), positioning it as a powerful early detection tool in kidney transplantation.
CareDx (NASDAQ:CDNA) announced significant advancements in AI-powered transplant diagnostics at the 2025 World Transplant Congress, featuring over 40 abstracts and 16 oral presentations. The company unveiled AlloSure® Plus, an AI-driven diagnostic platform integrated with EPIC Aura, validated through 2,700+ renal transplant biopsies by the Paris Transplant Group.
Key research findings include: an 8.166-fold increased risk of graft loss in kidney transplant recipients with elevated dd-cfDNA, successful monitoring of hard-to-place kidney transplants, and nearly doubled risk of complications in heart transplant recipients with elevated biomarkers. The company will host a symposium on August 4, 2025, focusing on precision molecular intelligence in transplant management.
CareDx (NASDAQ:CDNA), a company specializing in transplant healthcare solutions, has scheduled its second quarter 2025 financial results announcement for August 6, 2025, after market close.
The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can join via phone using the numbers 1-800-274-8461 (domestic) or 1-203-518-9814 (international) with Conference ID: CareDx, or through the webcast available on the company's investor relations website.
CareDx (NASDAQ:CDNA) announced a proposed draft Local Coverage Determination (LCD) that maintains coverage for surveillance testing in solid organ transplant rejection detection. The draft LCD, open for comments until August 31, 2025, continues to provide coverage for kidney, heart, and lung transplant surveillance testing without requiring protocol biopsy.
The policy introduces a bundled payment concept for surveillance testing. CareDx will provide additional information during its earnings call on August 6, 2025. The company's CEO, John W. Hanna, emphasized that this draft policy reinforces coverage for surveillance testing and supports their position on improving transplant patient outcomes.
CareDx (NASDAQ: CDNA), a precision medicine company specializing in transplant healthcare solutions, has announced its participation in three major upcoming investor conferences in May and June 2025:
- Craig-Hallum 22nd Annual Institutional Investor Conference in Minneapolis on May 28
- Jefferies Global Healthcare Conference 2025 in New York with a presentation on June 5 at 10:30 a.m. ET
- Goldman Sachs 46th Annual Global Healthcare Conference in Miami featuring a fireside chat on June 9 at 3:20 p.m. ET
Webcasts for the June 5th and June 9th events will be available through CareDx's Investor Relations website.
CareDx reported strong Q1 2025 financial results with total revenue reaching $84.7 million, an 18% year-over-year increase. The company achieved its seventh consecutive quarter of growth in testing services, with volume rising to 47,100 tests.
Key highlights include:
- Testing services revenue: $61.9 million (+15% YoY)
- Patient and Digital Solutions revenue: $12.0 million (+24% YoY)
- Product revenue: $10.8 million (+26% YoY)
While reporting a GAAP net loss of $10.4 million, the company showed significant improvement with non-GAAP net income of $5.4 million and positive adjusted EBITDA of $4.6 million. CareDx maintains a strong financial position with $231 million in cash and no debt. The company reaffirmed its 2025 revenue guidance of $365-375 million and introduced expanded indications for AlloSure Testing Services.